Sorry Twin I was not asking if cash would be a problem (after all there is always the ability to ask for more) but rather what buffer of cash on the balance sheet do you think is appropriate for the board to consider as a minimum to make sure the company can ride through any 'delays' or disappointments'.
I am not questioning if ADO has a great product but as the CEO and us other stakeholders have seen, in the Bio space things take a LOT longer than you would think.....so whats the number that a board should consider to be the minimum, 1 year of funding, 18 months, 6 months?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.75M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.2¢ | 1.1¢ | $13.47K | 1.172M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 4153063 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1164189 | 4 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| ADO (ASX) Chart |